Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus

Background. Antiplatelet therapy has become a standard therapeutic approach in the secondary prevention of cardiovascular system disorders of thrombotic origin. Patients with concomitant diabetes mellitus (DM) obtain fewer benefits from this treatment. Hence, the pathophysiology of altered platelet...

Full description

Bibliographic Details
Main Authors: Jakub Gawryś, Jerzy Wiśniewski, Ewa Szahidewicz-Krupska, Damian Gajecki, Julia Leśniewska, Filip Majda, Karolina Gawryś, Paulina Fortuna, Piotr Mlynarz, Adrian Doroszko
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Oxidative Medicine and Cellular Longevity
Online Access:http://dx.doi.org/10.1155/2020/6938629
id doaj-4534b38f60f94b538081e23f1fe06053
record_format Article
spelling doaj-4534b38f60f94b538081e23f1fe060532020-11-25T03:55:01ZengHindawi LimitedOxidative Medicine and Cellular Longevity1942-09001942-09942020-01-01202010.1155/2020/69386296938629Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes MellitusJakub Gawryś0Jerzy Wiśniewski1Ewa Szahidewicz-Krupska2Damian Gajecki3Julia Leśniewska4Filip Majda5Karolina Gawryś6Paulina Fortuna7Piotr Mlynarz8Adrian Doroszko9Department of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Medical Biochemistry Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Medical Biochemistry Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandDepartment of Biochemistry, Molecular Biology and Biotechnology, Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, PolandDepartment of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, PolandBackground. Antiplatelet therapy has become a standard therapeutic approach in the secondary prevention of cardiovascular system disorders of thrombotic origin. Patients with concomitant diabetes mellitus (DM) obtain fewer benefits from this treatment. Hence, the pathophysiology of altered platelet function in response to glucose metabolism impairment should be of particular interest. Objectives. The aim of our study was to verify if the platelet expression of the asymmetric dimethylarginine (ADMA) in diabetic patients differs in comparison to the nondiabetic ones. The correlation of platelet-ADMA with platelet activation and aggregation as well as with other risk factors was also investigated. Material and Methods. A total of 61 subjects were enrolled in this study, including thirty-one type 2 diabetic subjects without diabetes-related organ damage. Physical examination was followed by blood collection with an assessment of platelet aggregation, traditional biochemical cardiovascular risk factors, and evaluation of nitric oxide bioavailability parameters in plasma and thrombocytes. Subsequently, the assessment of endothelial function using Peripheral Arterial Tonometry and Laser Doppler Flowmetry (LDF) was performed. Results. In the DM group, elevated concentration of intraplatelet ADMA and higher ADMA/SDMA ratio compared to the control group was observed. It was accompanied by higher ADP-mediated platelet aggregation and lower microvascular response to a local thermal stimulus measured by LDF in the diabetes group. Conclusions. Type 2 diabetes is related to higher intraplatelet concentration of asymmetric dimethylarginine (ADMA), which may result in impaired platelet-derived nitric oxide synthesis and subsequent increased platelet activity, as assessed by the ADP-induced aggregation. Laser Doppler Flowmetry, compared to EndoPAT 2000, appears to be a more sensitive indicator of the impaired microvasculature vasodilation in diabetics without the presence of clinically significant target organ damage.http://dx.doi.org/10.1155/2020/6938629
collection DOAJ
language English
format Article
sources DOAJ
author Jakub Gawryś
Jerzy Wiśniewski
Ewa Szahidewicz-Krupska
Damian Gajecki
Julia Leśniewska
Filip Majda
Karolina Gawryś
Paulina Fortuna
Piotr Mlynarz
Adrian Doroszko
spellingShingle Jakub Gawryś
Jerzy Wiśniewski
Ewa Szahidewicz-Krupska
Damian Gajecki
Julia Leśniewska
Filip Majda
Karolina Gawryś
Paulina Fortuna
Piotr Mlynarz
Adrian Doroszko
Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
Oxidative Medicine and Cellular Longevity
author_facet Jakub Gawryś
Jerzy Wiśniewski
Ewa Szahidewicz-Krupska
Damian Gajecki
Julia Leśniewska
Filip Majda
Karolina Gawryś
Paulina Fortuna
Piotr Mlynarz
Adrian Doroszko
author_sort Jakub Gawryś
title Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
title_short Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
title_full Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
title_fullStr Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
title_full_unstemmed Increased Intraplatelet ADMA Level May Promote Platelet Activation in Diabetes Mellitus
title_sort increased intraplatelet adma level may promote platelet activation in diabetes mellitus
publisher Hindawi Limited
series Oxidative Medicine and Cellular Longevity
issn 1942-0900
1942-0994
publishDate 2020-01-01
description Background. Antiplatelet therapy has become a standard therapeutic approach in the secondary prevention of cardiovascular system disorders of thrombotic origin. Patients with concomitant diabetes mellitus (DM) obtain fewer benefits from this treatment. Hence, the pathophysiology of altered platelet function in response to glucose metabolism impairment should be of particular interest. Objectives. The aim of our study was to verify if the platelet expression of the asymmetric dimethylarginine (ADMA) in diabetic patients differs in comparison to the nondiabetic ones. The correlation of platelet-ADMA with platelet activation and aggregation as well as with other risk factors was also investigated. Material and Methods. A total of 61 subjects were enrolled in this study, including thirty-one type 2 diabetic subjects without diabetes-related organ damage. Physical examination was followed by blood collection with an assessment of platelet aggregation, traditional biochemical cardiovascular risk factors, and evaluation of nitric oxide bioavailability parameters in plasma and thrombocytes. Subsequently, the assessment of endothelial function using Peripheral Arterial Tonometry and Laser Doppler Flowmetry (LDF) was performed. Results. In the DM group, elevated concentration of intraplatelet ADMA and higher ADMA/SDMA ratio compared to the control group was observed. It was accompanied by higher ADP-mediated platelet aggregation and lower microvascular response to a local thermal stimulus measured by LDF in the diabetes group. Conclusions. Type 2 diabetes is related to higher intraplatelet concentration of asymmetric dimethylarginine (ADMA), which may result in impaired platelet-derived nitric oxide synthesis and subsequent increased platelet activity, as assessed by the ADP-induced aggregation. Laser Doppler Flowmetry, compared to EndoPAT 2000, appears to be a more sensitive indicator of the impaired microvasculature vasodilation in diabetics without the presence of clinically significant target organ damage.
url http://dx.doi.org/10.1155/2020/6938629
work_keys_str_mv AT jakubgawrys increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT jerzywisniewski increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT ewaszahidewiczkrupska increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT damiangajecki increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT julialesniewska increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT filipmajda increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT karolinagawrys increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT paulinafortuna increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT piotrmlynarz increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
AT adriandoroszko increasedintraplateletadmalevelmaypromoteplateletactivationindiabetesmellitus
_version_ 1715087764405354496